Americans pay more for their medicines than anyone else in the world – prices for the world’s top-selling 20 drugs are three times higher in the U.S. than in England, and two times higher than in Canada. In the wake of the 2016 Epipen and Daraprim drug pricing scandals, and as overall prices continue to climb, investors have grown frustrated by a lack of transparency on the part of the industry and believe a stronger message needs to be sent.
ICCR members argue that access to health care is a human right, and expect the pharmaceutical companies they hold in their portfolios to find ways to bend the cost curve to improve access and affordability for consumers
Featured ICCR Initiatives
Challenging 11 Pharma Companies. This proxy season, ICCR members have filed resolutions with 11 major U.S. pharmaceutical companies and sent letters to an additional six non U.S. companies requesting that they provide rationale and criteria that justify price increases along with an assessment of the legislative, regulatory, reputational and financial risks they represent to these companies. Read the letter
Open Letter to Congress in Support of Legislation to Improve Access to Affordable Prescription Drugs. In April, ICCR joined a coalition of onsumer and grassroots advocates, public health experts, healthcare providers and clinical researchers across the country, in applauding via an open letter, the bicameral introduction of The Improving Access to Affordable Prescription Drugs Act.
The Access to Medicines Index - The Index analyses 20 of the world’s largest research-based pharmaceutical companies on how they make medicines, vaccines and diagnostics more accessible in low- and middle-income countries
The Human Toll of Unaffordable Medicines - Five stories of Americans struggling with the cost of everyday medicines.